---
title: "興利集團斥 8,150 萬元購入帝景園單位連車位"
description: "興利集團公佈，其間接全資附屬興利物業，向 Dipende 購入香港舊山頂道 23 號帝景園 2 座 18 樓 B 室，連同帝景園 LG4 層第 6 號停車位，代價為 8,150 萬元。"
type: "news"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/263471835.md"
published_at: "2025-10-30T09:06:08.000Z"
---

# 興利集團斥 8,150 萬元購入帝景園單位連車位

> 興利集團公佈，其間接全資附屬興利物業，向 Dipende 購入香港舊山頂道 23 號帝景園 2 座 18 樓 B 室，連同帝景園 LG4 層第 6 號停車位，代價為 8,150 萬元。

興利集團 (00114.HK) 公佈，其間接全資附屬興利物業，向 Dipende 購入香港舊山頂道 23 號帝景園 2 座 18 樓 B 室，連同帝景園 LG4 層第 6 號停車位，代價為 8,150 萬元。

### Related Stocks

- [00114.HK - 興利集團](https://longbridge.com/zh-HK/quote/00114.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Standard Chartered PLC (OTCMKTS:SCBFF) Sees Significant Growth in Short Interest | Standard Chartered PLC (OTCMKTS:SCBFF) experienced a significant increase in short interest, rising 21.1% to 210,583 sha | [Link](https://longbridge.com/zh-HK/news/276119010.md) |
| Beijing Haizhi Technology Announces Final Offer Price | Beijing Haizhi Technology Group Co Ltd:FINAL OFFER PRICE HK$27.06 PER H SHARE UNDER GLOBAL OFFERING | [Link](https://longbridge.com/zh-HK/news/275780031.md) |
| CSPC Pharmaceutical says ropivacaine long-acting injection approved for clinical trials in China | CSPC Pharmaceutical says ropivacaine long-acting injection approved for clinical trials in China | [Link](https://longbridge.com/zh-HK/news/276051793.md) |
| Will China Literature Turn The Page? | China Literature Ltd. expects a net loss of up to 850 million yuan for last year, primarily due to a 1.8 billion yuan go | [Link](https://longbridge.com/zh-HK/news/276113491.md) |
| CSPC Pharmaceutical Receives Regulatory Nods to Begin Drug Trials | CSPC Pharmaceutical Receives Regulatory Nods to Begin Drug Trials | [Link](https://longbridge.com/zh-HK/news/276035104.md) |

---

> **免責聲明**：本文內容僅供參考，不構成任何投資建議。